759 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Hudson Value Partners LLC

Hudson Value Partners LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 759 shares of the biopharmaceutical company’s stock, valued at approximately $398,000.

Other hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $343,764,000. Pacer Advisors Inc. increased its position in Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after acquiring an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock valued at $305,311,000 after acquiring an additional 303,785 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after acquiring an additional 121,545 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 6.7%

Regeneron Pharmaceuticals stock opened at $599.94 on Thursday. The company’s 50 day simple moving average is $570.67 and its 200 day simple moving average is $568.93. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,045.95. The firm has a market capitalization of $63.59 billion, a price-to-earnings ratio of 15.12, a PEG ratio of 1.79 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm earned $11.56 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on REGN shares. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.